Goodbody Health (Previously Sativa Wellness Group) Announces a New Sponsorship Agreement With James Hedley
VANCOUVER, BC / ACCESSWIRE / January 20, 2022 / Goodbody Health Inc. (CSE:GDBY) ("Goodbody Health" or the "Company") is pleased...
Month: January 2022
Icario Celebrates Year of Record Growth and Impact
Strong Company Momentum Advances Icario’s Mission of Making the World a Healthier PlaceMINNEAPOLIS, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Icario,...
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
Top-line data anticipated in the second quarter of 2022SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:...
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation...
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Tuesday, January 25that 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) --...
Healthcare Triangle, Inc. Releases Shareholder Update
Highlights Market Opportunity and Recent Accretive Acquisition Awarded Top 100 Premier Partner Status at Amazon World Services & Premier Partner Status...
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global...
Akoya Biosciences Appoints Marilee Moy as Chief People Officer
Ms. Moy brings 30 years of HR leadership experience at high-performing companies Marilee Moy Marilee Moy, Chief People Officer, Akoya...
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE)...
First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in...
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...
NGM Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company...
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing...
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first...
Origin Therapeutics Portfolio Company Posts Strong 2021 Following Successful Miami Conference
Microdose Psychedelic Insights’ Wonderland: Miami conference was the largest in-person conference in the psychedelic medicine business.Vancouver, British Columbia, Jan. 20,...
Chimerix to Present at B. Riley Virtual Oncology Conference
DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that...
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular TherapyMIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE)...
Boost Your 2022 Wellness Routine With Manitoba Harvest
Manitoba Harvest Shares NEW Delicious Recipes Compatible with Vegan, Keto, Paleo, and Gluten-Free Diets Manitoba Harvest Hemp Hearts Manitoba Harvest...